Month: June 2022

In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after five years1Nearly half (49%) of those in remission stayed in remission after a median follow-up of 5.5 years, demonstrating the long-term benefit and curative potential of one-time Kymriah infusion1The safety profile remains consistent with previously reported results, without late adverse effects in these heavily pretreated patients1Novartis is committed to delivering transformative CAR-T cell therapies with these longer-term data, recent regulatory approvals for Kymriah in r/r follicular lymphoma and ongoing development of T-Charge™ platformBasel, June 12, 2022 — Novartis today announced long-term five-year follow-up results from the ELIANA...

In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than five years144% of patients who experienced remission within three months of infusion were still in remission at the five-year mark, demonstrating the long-term benefit and curative potential of one-time Kymriah infusion1The safety profile remains consistent with previously reported results, without late adverse effects in these heavily pretreated patients1Novartis is committed to delivering transformative CAR-T cell therapies with these longer-term data, recent regulatory approvals for Kymriah in r/r follicular lymphoma and ongoing development of T-Charge™ platformBasel, June 12, 2022 — Novartis today announced long-term results...

PEACE RIVER, Alberta, June 11, 2022 (GLOBE NEWSWIRE) — Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC) is deeply saddened to announce that an independent contractor’s employee suffered a tragic and fatal workplace accident at our Peace River mill in Peace River, Alberta on June 11, 2022. Mercer has initiated an incident investigation and is fully cooperating with the authorities. “We are saddened about the loss of life of one of our contractor’s employees and our thoughts are with the individual’s family and colleagues. An investigation of the accident has been started and we are working with the authorities and the contracting company to find out how this tragic incident occurred,” stated Roger Ashfield, Managing Director of Mercer Peace River. “Mercer’s emergency procedures were immediately activated...

TORONTO, June 11, 2022 (GLOBE NEWSWIRE) — It is with great sorrow that Rogers Communications Inc. (“Rogers”) today announces the passing of Loretta Rogers at the age of eighty-three, peacefully in her home, surrounded by family.  A beloved wife to the late Ted Rogers, mother, and grandmother, Loretta lived a full and vibrant life who dedicated herself to family, friendship, community and business. Loretta believed passionately in Ted’s vision for the company, and through 45 years of a deeply loving marriage, Loretta and Ted supported each other to grow Rogers into the company that it is today. Following Ted’s death, Loretta devoted herself to keeping his vision alive and making Rogers the absolute best it could be.   Mrs. Rogers served as a corporate director of Rogers Communications since 1964 and was a member of the...

Richard M. McCool Jr. (LPD 29) Christening Ship’s Sponsors Shana McCool and Kate Oja christened Richard M. McCool Jr. (LPD 29), the U.S. Navy’s 13th San Antonio-class amphibious transport dock at HII’s Ingalls Shipbuilding division. LPD 29 is named for McCool and Oja’s grandfather, Capt. Richard M. McCool Jr., a Medal of Honor recipient.Also pictured are Capt. Jeffrey Baker, prospective commanding officer, Richard M. McCool Jr. (LPD 29); Kari Wilkinson, Ingalls Shipbuilding president; and Erik Raven, under secretary of the Navy.PASCAGOULA, Miss., June 11, 2022 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Ingalls Shipbuilding division christened the company’s 13th amphibious transport dock, Richard M. McCool Jr. (LPD 29), constructed for the U.S. Navy. “For nearly two decades, we have had the opportunity...

-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90% of patients- -Well tolerated safety profile across all dose levels with no DLTs observed- ZUG, Switzerland and CAMBRIDGE, Mass., June 11, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented positive results from the Company’s ongoing Phase 1 COBALT™-LYM trial evaluating the safety and efficacy of CTX130™, its wholly-owned allogeneic CAR-T cell therapy targeting CD70 for the treatment of both solid tumors and certain hematologic malignancies. “We are very pleased with the preliminary results from our COBALT-LYM...

Provided is the additional information for the Extraordinary General Meeting of Shareholders (hereinafter – the Meeting) of Snaige AB (hereinafter – Company) which is convened on June 23rd, 2022 10 a.m. on the agenda item No. 2 .: Regarding the approval of the project of the Company’s restructuring plan. The Company’s shareholders are invited to participate in the Meeting and vote on the agenda items in writing, by filling voting ballot in advance and submitting to the Company (by address Pramones str. 6, Alytus, Lithuania). The document confirming the right to vote must also be sent together with voting ballot. Based on the COVID-19 morbidity rates in the country it is recommended to firstly consider the possibilities of receiving the General Voting Ballot and advance voting remotely, and to come to the Company’s...

Figure 1 Planned 2022 Joss Drill TargetsTORONTO, June 11, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), is pleased to announce that it has resumed drilling on the high-grade Joss target at the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA. Approximately 2,000 meters of core drilling in three holes are planned this summer at Joss. Drilling will focus on the continued definition and expansion of the one-kilometer trend of high-grade gold mineralization with underground mining and mill potential. High-grade intercepts from the eighteen core holes previously drilled on the Joss trend typically run from 4–11 g/t gold and are estimated to range between 1–5 meters in true width (see Revival Gold press release dated March 1st, 2021). Drilling...

With reference to company announcement of 25 April 2022 regarding the general meeting’s approval of share capital reduction, Park Street A/S hereby announces that completion of the share capital reduction has now been registered with the Danish Business Authority. The nominal value of the share capital reduction is DKK 10,338,160 corresponding to 10,338,160 shares of nominal value of DKK 1 held by Park Street A/S as treasury shares prior to the registration. Accordingly, Park Street A/S’ share capital is now reduced from DKK 67,513,732 to DKK 57,175,572. Consequently, Park Street A/S no longer holds any class A treasury shares nor any class B treasury shares. Prior to the share capital reduction, the treasury shares held by Park Street A/S corresponded to 15.31% of the company’s total share capital. In accordance with Section 31 of the...

Media Release COPENHAGEN, Denmark; June 11, 2022 Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR; patients previously treated with CAR T achieved a 54 percent ORR and 34 percent CR Manageable safety profile consistent with previous findings was observed Results were reported as part of a late-breaking oral presentation selected for the Presidential Symposium at the EHA Annual CongressGenmab A/S (Nasdaq: GMAB) announced today primary results from the large B-cell lymphoma (LBCL) expansion cohort in the...